Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

162.98 +3.09 (+1.93%)

Delayed Quote Updated: 12:17 PM EST, Nov 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

23 24 Next >

Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023 ↗

March 21, 2023

Via Benzinga

Analyst Ratings for Alnylam Pharmaceuticals ↗

March 21, 2023

Via Benzinga

3 Growth Stocks That Could Disrupt the Healthcare Industry ↗

March 13, 2023

These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time.

Via InvestorPlace

Alnylam Announces Appointment of Peter Kellogg to Board of Directors

March 08, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals's Return On Capital Employed Insights ↗

February 27, 2023

Via Benzinga

Analyst Ratings for Alnylam Pharmaceuticals ↗

February 24, 2023

Via Benzinga

Looking Into Alnylam Pharmaceuticals's Recent Short Interest ↗

March 03, 2023

Alnylam Pharmaceuticals's (NASDAQ:ALNY) short percent of float has fallen 5.3% since its last report. The company recently reported that it has 5.10 million shares sold short, which is 4.82% of all...

Via Benzinga

Alnylam to Webcast Presentations at Upcoming March Investor Conferences

March 01, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity

February 23, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023 ↗

February 21, 2023

Via Benzinga

Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

February 21, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results

February 02, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Five Best And Worst Performing Healthcare Stocks In December 2022 ↗

January 22, 2023

Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023 ↗

January 18, 2023

Via Benzinga

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates

January 08, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

3 Growth Stocks That Could Rocket Higher in 2023 ↗

January 06, 2023

Upcoming binary events could push these stocks to new all-time highs.

Via The Motley Fool

Alnylam Announces Updates to its Board of Directors

January 05, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes

December 21, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Meta To Rally Over 29%? Here Are 10 Other Price Target Changes For Friday ↗

December 16, 2022

Via Benzinga

Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day

December 15, 2022

From Alnylam Pharmaceuticals

Via Business Wire

Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

December 08, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Virtual R&D Day

December 08, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims ↗

December 06, 2022

Via Benzinga

Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022

December 01, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

November 09, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Looking Into Alnylam Pharmaceuticals's Return On Capital Employed ↗

November 02, 2022

Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q3 sales of $264.31 million. Earnings fell to a loss of $405.92 million, resulting in a 46.33% decrease from last quarter.

Via Benzinga

What 11 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

November 02, 2022

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:

Via Benzinga

Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year

October 27, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Scraps Interim Analysis For Heart Disease Trial, Rethinks Plans For Another Rare Disorder Program ↗

October 27, 2022

Via Benzinga

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.